Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Avernus Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Benuvia Licenses SYNDROS® CII to Avernus Pharma for Gulf Cooperation Region
Details : Under the terms of the licensing agreement, Avernus will become the supplier for Syndros (dronabinol). It is indicated for treating anorexia associated with weight loss in patients with AIDS.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Avernus Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Medra Brasil Medicamentos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Benuvia Enters Licensing and Supply Agreements with Medra Brasil Medicamentos
Details : Medra Brasil will become the exclusive supplier for Syndros (dronabinol), oral solution, CII in the country of Brazil following approval by the Brazilian Health Regulatory Agency (Anvisa).
Product Name : Syndros
Product Type : Small molecule
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Medra Brasil Medicamentos
Deal Size : Undisclosed
Deal Type : Licensing Agreement